Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
1. Claims 1, 24, 25, 30, 70 are amended. Claims 2-4, 10-23, 28-29, 31-55, 57, 62, 63, 67, 68 are canceled. Claims 8, 9, 27, 56, 58-61, 64-66, 69 are withdrawn. New claim 71 is added. Claims 1, 5-7, 24-26, 30, 70, 71 are under consideration.
Information Disclosure Statement
2. The information disclosure statements (IDS) were submitted on 5/6/2026; 7/14/2026; 7/23/2026; 9/24/2026. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Specification
3. (previous objection, withdrawn) The disclosure was objected to because of informalities.
Applicant contends: the specification has been amended.
In view of applicant’s amendments, the objection is withdrawn.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
4. (previous rejection, maintained as to claims 1, 5-7, 24-26, 30, 70; new, necessitated by amendment as to claims 70, 71) Claims 1, 5-7, 24-26, 30, 70, 71 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre- AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre- AIA 35 U.S.C. 112, the applicant), regards as the invention.
See claims 1, 5-7, 24-26, 30, 70, 71 as submitted 7/1/2026.
Applicant contends: claim 1 has been amended; the circumstance is outside the scope of the claim; a claim is not required to expressly recite every hypothetical circumstance; claims have been amended.
Applicant’s arguments are considered and found persuasive in part and unpersuasive in part.
See the rejection as recited in the previous Office Action.
Applicant’s arguments are persuasive as to previously raised points in amended claims 24, 25, 30, and thus the rejection is withdrawn.
The rejection is however maintained as to claim 1, as it is still not clear what the outcomes or steps are if the score is above the first predetermined level or below a second predetermined level, or if the step is no treatment. Claims 5-7, 24-26, 30 depend on this claim.
The rejection is maintained as to claim 70 as the claim still recites “non-infectious subjects”, and it is not clear if the claim intends to recite “non-infected subjects”. New as to amended claim 70, the claim merely recites “diagnose the subject”. It is not clear what the subject is being diagnosed for, or if the claim intends to recite “to diagnose the infection of the subject” or not.
New as to claim 71, the claim recites “performing an additional test to identify the infection type when the score is above the first predetermined level and below the second predetermined level.” It is not clear if performing an additional test takes place when the score is above the first predetermined level “and/or” below the second predetermined level, or if both conditions (above the first predetermined level and below the second predetermined level) are required to perform the additional test.
The rejection is maintained and extended for reasons of record.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
5. (previous rejection, maintained; withdrawn as to claim 70; new, necessitated by amendment as to claim 71) Claims 1, 5-7, 24-26, 30, 71 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception without significantly more. This judicial exception is not integrated into a practical application and the claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception for the reasons set forth below.
See claims 1, 5-7, 24-26, 30, 71 as submitted 7/1/2026.
See also the 35 U.S.C. 112(b) rejection above.
Applicant contends: analogous to Example 29, administration of antiviral agents or antibiotics converts the currently claimed subject matter to eligible subject matter; claim 1 is amended and does not encompass merely obtaining diagnostic information or observing a natural correlation; every performance of the claimed method culminates in administration of a specific therapeutic agent; claims 70, 71 have been amended to require that additional diagnostic testing be performed, thus, every possible outcome results in a specific clinical action; as in Example 29, these steps amount to significantly more than the judicial exception; the claims are patent eligible.
Applicant’s arguments are considered and found persuasive as to claim 70 for which the rejection is withdrawn but unpersuasive as to claim 1. New claim 71 is also rejected.
See the rejection as recited in the previous Office Action.
As to amended claim 1 (and claims 5-7, 24-26, 30 that depend on claim 1), and new claim 71, there still appear to be outcomes for which the next step is “no treatment” or decision not to treat. While amendments are noted as to claim 1, there still appears to be “no treatment” when the score is above the first predetermined level, as well as when the score is below a second predetermined level. As previously indicated, the claim is then still directed towards generating a score based on determined levels which are mathematical concepts and the mental steps of correlating score with infection (judicial exceptions in the form of a law of nature and abstract ideas), additional embodiments wherein the determination or decision appears to be not to treat (embodiments that do not recite additional elements that integrate the JE into a practical application), and the claims do not recite additional elements that amount to significantly more than the judicial exception (wherein as indicated the instant claims only recite data-gathering steps and insignificant extra-solution activity).
As to claim 71, and in view of the indefiniteness as indicated in Item #4 above, it still appears there is “no treatment” or decision not to treat when the score is merely above the first predetermined level, or when the score is below a second predetermined level, or when the score is above a predetermined first level and above the second predetermined level, or when the score is below the first predetermined level and below the second predetermined level. As such the claim reads on additional embodiments wherein the determination or decision appears to be not to treat. As such the instant claim reads on embodiments that do not recite additional elements that integrate the JE into a practical application, and further the claim does not recite additional elements that amount to significantly more than the judicial exception. As indicated previously in Oved et al., Eden et al., Oved et al.-2, and Tsalik et al. and as the instant claim recites "comprising" and is interpreted in an open-ended fashion and does not exclude other RNAs (See MPEP 211), it is well-understood, routine, and conventional at the time of filing to use expression levels of RNA determinants including IFI44L (Table 3 in Eden et al.) and CD177 (Table 1 in Eden et al.), among many other RNAs, to compare, determine and diagnose type of infection. As such, beyond the JE, the instant claim only recites data-gathering steps. These data-gathering steps constitute insignificant extra-solution activity, and the instant claim reads upon embodiments wherein there is no apparent decision to treat. As such, the instant claim does not recite significantly more than the JE, and accordingly, the instant claim does not constitute patent eligible subject matter under 35 U.S.C § 101.
The rejection is maintained and extended for reasons of record.
Conclusion
6. No claims are allowed.
7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to M FRANCO G SALVOZA whose telephone number is (571)272-4468. The examiner can normally be reached M-F 8:00 to 5:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone can be reached at 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/M FRANCO G SALVOZA/Primary Examiner, Art Unit 1672